| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-25,779 | -22,063 | -20,578 | -14,731 | -23,403 | ||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||
Amortization of debt discount on notes payable | ||||||
0 | 404 | 1,283 | 1,788 | 893 | ||
Amortization of investment premiums (accretion of investment discounts), net | ||||||
477 | 73 | 95 | 153 | 131 | ||
Amortization of financing costs | ||||||
146 | 120 | 571 | 138 | - | ||
Amortization of non-cash clinical trial costs | ||||||
140 | 666 | 994 | - | - | ||
Change in fair value of accrued license fees | ||||||
- | - | - | - | -9,381 | ||
Change in fair value of debt conversion feature liability | ||||||
0 | 1,398 | 345 | 1,064 | -1,043 | ||
Stock-based compensation | ||||||
3,743 | 2,608 | 1,451 | 1,794 | 2,601 | ||
Amortization of right-of-use assets | ||||||
260 | - | - | - | - | ||
Interest expense related to operating lease liability | ||||||
48 | - | - | - | - | ||
Realized (gain) loss on investments | ||||||
-4 | 12 | - | - | - | ||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
7,380 | 137 | -497 | -273 | 1,079 | ||
Deposits | ||||||
- | - | - | -40 | 79 | ||
Accounts payable | ||||||
1,472 | -508 | 264 | 677 | 219 | ||
Accrued expenses | ||||||
2,394 | 1,468 | 1,010 | -141 | 1,560 | ||
Lease liability | ||||||
-269 | - | - | - | - | ||
Net cash used in operating activities | ||||||
-24,752 | -18,755 | -14,758 | -11,071 | -8,731 | ||
Purchases of investments | ||||||
362,406 | 348,204 | 22,526 | 16,922 | 16,033 | ||
Proceeds from maturities of investments | ||||||
369,869 | 82,475 | 20,796 | 19,952 | 2,563 | ||
Net cash provided by (used in) investing activities | ||||||
7,463 | -265,729 | -1,730 | 3,029 | -13,470 | ||
Proceeds from issuances of common stock, net of underwriting discounts and commissions | ||||||
- | 296,607 | 22,352 | 11,548 | 25,392 | ||
Public offering and financing costs | ||||||
73 | 765 | 500 | 1,096 | 2,782 | ||
Value of shares withheld related to employee tax withholding | ||||||
151 | 127 | 22 | 31 | 418 | ||
Repurchases of common stock | ||||||
- | - | - | 0 | 0 | ||
Repayment of convertible notes payable | ||||||
- | 3,833 | 77 | 94 | - | ||
Proceeds from stock issuance under employee stock purchase plan and warrant exercises | ||||||
1,111 | 8,393 | 647 | 22 | - | ||
Proceeds from stock issuance under employee stock purchase plan | ||||||
- | - | - | - | 22 | ||
Net cash provided by financing activities | ||||||
887 | 300,275 | 22,400 | 10,348 | 22,214 | ||
Net increase (decrease) in cash and cash equivalents | ||||||
-16,402 | 15,791 | 5,912 | 2,306 | 12 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest | ||||||
- | 81 | 123 | 205 | - | ||
Supplemental disclosure of non-cash investing and financing transactions | ||||||
Shares issued | ||||||
- | - | 1,800 | - | - | ||
Shares issued in lieu of license fee payment | ||||||
- | - | - | - | 29,247 | ||
Unpaid deferred public offering and other financing costs | ||||||
50 | - | 140 | - | 108 | ||
Receivable from exercise of warrants | ||||||
10 | - | 104 | - | - | ||
Shares issued in lieu of loan payment to related party | ||||||
- | - | - | 1,200 | - | ||
Conversion of notes payable | ||||||
- | - | - | - | 456 | ||
Issuance of common stock to consultant | ||||||
- | - | - | - | 28 | ||
Lincoln Park Agreement [Member] | ||||||
Shares issued | ||||||
- | - | 180 | - | - | ||